[Safety and effectiveness of oncolytic viruses in advanced cancer. systematic review of the literature]

De Prado Hidalgo MJ, Llanos Mendez A
Record ID 32013000032
Spanish
Authors' recommendations: Oncolytic viruses are located, along with other gene treatment alternatives (gene-therapy), within the new biological treatments of cancer, characterized by specifically and selectively blocking concrete aspects of the cell or tumor biology. • Genetically modified viruses acquire a greater selectivity for tumor cells and capacity for replication and lysis in their interior without affecting healthy tissue, thus achieving a better profile of adverse effects. • To evaluate the safety and effectiveness, a systematic search was carried out on preset bases, which recovered ten treatment studies with genetically modified viruses in a series of cases of patients with different types of cancer in advanced stages. • The methodological quality was limited by the absence of a control group and the smallness of the sample; also by numerous and heterogeneous co-treatments, together with the variability in the use of the doses, which hindered the identification of the true effect of the viral treatment. • The results of the experimentation pointed to a good safety profile, although the results regarding effectiveness seemed modest in their application in advanced tumors. • The real effectiveness regarding a cure or a delay in the evolution of the cancer is still to be proven. New studies with higher quality design are necessary to show the benefits in the improvement of the response by the tumor.
Details
Project Status: Completed
URL for project: https://www.aetsa.org/publicacion/seguridad-y-eficacia-de-los-virus-oncoliticos-en-el-cancer-avanzado-revision-sistematica/
Year Published: 2012
URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2011_2-3_virus_oncoliticos.pdf
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Spain
MeSH Terms
  • Humans
  • Neoplasms
  • Oncolytic Viruses
Contact
Organisation Name: Andalusian Health Technology Assessment Area
Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name: aetsa.csalud@juntadeandalucia.es
Contact Email: aetsa.csalud@juntadeandalucia.es
Copyright: Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.